Vanguard Group Inc. Has $422.17 Million Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Vanguard Group Inc. grew its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 0.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,034,862 shares of the biopharmaceutical company's stock after purchasing an additional 89,389 shares during the period. Vanguard Group Inc. owned about 10.87% of Ultragenyx Pharmaceutical worth $422,167,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in RARE. Smartleaf Asset Management LLC lifted its position in Ultragenyx Pharmaceutical by 259.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 493 shares in the last quarter. Human Investing LLC purchased a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter valued at $42,000. Van ECK Associates Corp increased its stake in shares of Ultragenyx Pharmaceutical by 18.4% in the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock worth $74,000 after acquiring an additional 273 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Ultragenyx Pharmaceutical in the third quarter worth $83,000. Finally, Nomura Asset Management Co. Ltd. purchased a new stake in shares of Ultragenyx Pharmaceutical during the third quarter worth $93,000. 97.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, insider John Richard Pinion sold 14,439 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $607,881.90. Following the sale, the insider now owns 107,766 shares of the company's stock, valued at $4,536,948.60. The trade was a 11.82 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Emil D. Kakkis sold 25,000 shares of the firm's stock in a transaction dated Friday, February 28th. The stock was sold at an average price of $42.48, for a total transaction of $1,062,000.00. Following the transaction, the chief executive officer now directly owns 2,158,985 shares of the company's stock, valued at $91,713,682.80. The trade was a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 124,643 shares of company stock valued at $5,256,268 in the last ninety days. Company insiders own 5.80% of the company's stock.

Remove Ads

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ RARE traded down $0.29 during trading hours on Monday, hitting $32.14. 1,170,671 shares of the company's stock were exchanged, compared to its average volume of 795,159. The stock has a market capitalization of $3.02 billion, a price-to-earnings ratio of -5.07 and a beta of 0.61. The company's 50-day moving average price is $40.61 and its 200-day moving average price is $45.75. Ultragenyx Pharmaceutical Inc. has a 1-year low of $30.45 and a 1-year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The business had revenue of $164.88 million during the quarter, compared to the consensus estimate of $163.23 million. On average, research analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on RARE shares. Wells Fargo & Company upped their target price on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an "overweight" rating in a research report on Friday, December 20th. Wedbush reaffirmed a "neutral" rating and set a $48.00 price objective (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research report on Monday, January 13th. Piper Sandler reduced their target price on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating for the company in a research note on Monday, March 17th. HC Wainwright restated a "buy" rating and set a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. Finally, Canaccord Genuity Group lifted their price objective on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a research note on Tuesday, February 18th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $92.79.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.